PubMed Health⌕ Search

PubMed · 16465715

Selectivity toward multiple predetermined targets in nanoparticle capillary electrochromatography.

Abstract

Two unique methods to achieve selectivity toward multiple predetermined targets employing molecular imprinting technology have been developed. Partial filling capillary electrochromatography (CEC) was utilized to evaluate and compare the two techniques. The first approach, the mixed singly templated molecularly imprinted polymer (MIP) nanoparticle approach, is based on the mixing of two types of MIP nanoparticles with inherently different selectivity. The second approach, the multiply templated MIP nanoparticle approach, is based on the incorporation of two different templates during the preparation of the MIP nanoparticles. The use of MIPs in analytical chemistry applications has been extensively investigated during the past years. However, MIP nanoparticles with tailored multiple selectivity toward predetermined enantiomers has not yet been explored. The relative amounts of the two templates studied, i.e., (S)-ropivacaine and (S)-propranolol, were found to strongly affect the affinity of the multiply templated MIP nanoparticles for the predetermined targets. The amount of (S)-propranolol template had to be decreased to concentrations rarely applied in MIP synthesis in order to achieve 2-fold selectivity. Even though strongly decreased to 10% of the usual concentration employed, the MIP could efficiently separate the enantiomers of propranolol when applied in partial filling CEC. This opens up for new possibilities to decrease the need for an initial high amount of template in order to be able to produce an efficient MIP. The multiple enantiomer separation ability of the multiply templated MIP nanoparticles was compared with that of singly templated MIP nanoparticles that were mixed prior to analysis. It was concluded that the multiply templated MIP potentially can offer many new and interesting applications in chromatography as well as in sensor technology and solid-phase extraction.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Peter Spégel, Leif Schweitz, Staffan Nilsson. 2003-12-01. Selectivity toward multiple predetermined targets in nanoparticle capillary electrochromatography.. https://doi.org/10.1021/ac034732w

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗